Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Vomiting 39 Nausea 31 Neoplasms 10 Breast Neoplasms 10 Lymphoma 9 Multiple Myeloma 7 Ovarian Neoplasms 6 Lymphoma, Non-Hodgkin 6 Leukemia, Myeloid, Acute 6 Sezary Syndrome 4 Myeloproliferative Disorders 4 Leukemia 4 Pruritus 3 Primary Myelofibrosis 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Pdgfra-Associated Chronic Eosinophilic Leukemia 3 Neoplasms, Plasma Cell 3 Myelodysplastic Syndromes 3 Mycosis Fungoides 3 Lymphoma, T-Cell, Cutaneous 3 Lymphoma, Mantle-Cell 3 Lymphoma, Large-Cell, Immunoblastic 3 Lymphoma, Large B-Cell, Diffuse 3 Lymphoma, Follicular 3 Lymphoma, B-Cell, Marginal Zone 3 Leukemia, Neutrophilic, Chronic 3 Leukemia, Myelomonocytic, Chronic 3 Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 3 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3 Leukemia, Lymphocytic, Chronic, B-Cell 3

Interventions

fexofenadine 1 Prednisone 1 Aprepitant 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × ITCH × Aprepitant × Clear all

NCT01683552 2012-09-12

AprepIt

Campus Bio-Medico University

Phase 2 Completed

ITCH

Data powered by HemOnc (CC BY 4.0) Colophon ⚡